HAE Quote, Financials, Valuation and Earnings

Enovis Corp. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of -104%. Haemonetics Corp.'s return on equity of 19.39% beat Enovis Corp.'s return on equity of -52.07%.

Haemonetics Corp. has a consensus price target of $84.55, signalling upside risk potential of 0.72%. On the other hand Enovis Corp. has an analysts' consensus of $48.11 which suggests that it could grow by 78.06%. Given that Enovis Corp. has higher upside potential than Haemonetics Corp., analysts believe Enovis Corp. is more attractive than Haemonetics Corp..

Haemonetics Corp. has a beta of 0.301, which suggesting that the stock is 69.913% less volatile than S&P 500. In comparison Enovis Corp. has a beta of 1.284, suggesting its more volatile than the S&P 500 by 28.371%.

Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Enovis Corp. pays out -- of its earnings as a dividend.

Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Enovis Corp. quarterly revenues of $548.9M. Haemonetics Corp.'s net income of $38.7M is higher than Enovis Corp.'s net income of -$570.9M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 24.49x while Enovis Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 3.10x versus 0.69x for Enovis Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 14.46%. Haemonetics Corp.'s return on equity of 19.39% beat Masimo Corp.'s return on equity of -19.18%.

Haemonetics Corp. has a consensus price target of $84.55, signalling upside risk potential of 0.72%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 29.69%. Given that Masimo Corp. has higher upside potential than Haemonetics Corp., analysts believe Masimo Corp. is more attractive than Haemonetics Corp..

Haemonetics Corp. has a beta of 0.301, which suggesting that the stock is 69.913% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.

Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Haemonetics Corp.'s net income of $38.7M is lower than Masimo Corp.'s net income of $53.7M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 24.49x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 3.10x versus 4.48x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

UFP Technologies, Inc. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 10.6%. Haemonetics Corp.'s return on equity of 19.39% beat UFP Technologies, Inc.'s return on equity of 18.42%.

Haemonetics Corp. has a consensus price target of $84.55, signalling upside risk potential of 0.72%. On the other hand UFP Technologies, Inc. has an analysts' consensus of $329.50 which suggests that it could grow by 51.75%. Given that UFP Technologies, Inc. has higher upside potential than Haemonetics Corp., analysts believe UFP Technologies, Inc. is more attractive than Haemonetics Corp..

Haemonetics Corp. has a beta of 0.301, which suggesting that the stock is 69.913% less volatile than S&P 500. In comparison UFP Technologies, Inc. has a beta of 1.103, suggesting its more volatile than the S&P 500 by 10.324%.

Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UFP Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. UFP Technologies, Inc. pays out -- of its earnings as a dividend.

Haemonetics Corp. quarterly revenues are $327.3M, which are larger than UFP Technologies, Inc. quarterly revenues of $154.6M. Haemonetics Corp.'s net income of $38.7M is higher than UFP Technologies, Inc.'s net income of $16.4M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 24.49x while UFP Technologies, Inc.'s PE ratio is 25.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 3.10x versus 2.83x for UFP Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona, Inc. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of -47.35%. Haemonetics Corp.'s return on equity of 19.39% beat Dentsply Sirona, Inc.'s return on equity of -44.58%.

Haemonetics Corp. has a consensus price target of $84.55, signalling upside risk potential of 0.72%. On the other hand Dentsply Sirona, Inc. has an analysts' consensus of $12.96 which suggests that it could grow by 15.24%. Given that Dentsply Sirona, Inc. has higher upside potential than Haemonetics Corp., analysts believe Dentsply Sirona, Inc. is more attractive than Haemonetics Corp..

Haemonetics Corp. has a beta of 0.301, which suggesting that the stock is 69.913% less volatile than S&P 500. In comparison Dentsply Sirona, Inc. has a beta of 1.008, suggesting its more volatile than the S&P 500 by 0.82100000000001%.

Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona, Inc. offers a yield of 5.69% to investors and pays a quarterly dividend of $0.16 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Dentsply Sirona, Inc. pays out 13.85% of its earnings as a dividend. Dentsply Sirona, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Dentsply Sirona, Inc. quarterly revenues of $904M. Haemonetics Corp.'s net income of $38.7M is higher than Dentsply Sirona, Inc.'s net income of -$428M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 24.49x while Dentsply Sirona, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 3.10x versus 0.62x for Dentsply Sirona, Inc.. Usually stocks with elevated PS ratios are considered overvalued.